Abstract

IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy

Front Immunol. 2024 Apr 15:15:1331217. doi: 10.3389/fimmu.2024.1331217.eCollection 2024.

 

James G Krueger 1Kilian Eyerich 2 3Vijay K Kuchroo 4Christopher T Ritchlin 5Maria T Abreu 6M Merle Elloso 7Anne Fourie 8Steven Fakharzadeh 9Jonathan P Sherlock 10 11Ya-Wen Yang 9Daniel J Cua 10Iain B McInnes 12

 
     

Author information

1Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, United States.

2Department of Medicine, Division of Dermatology and Venereology, Karolinska Institute, Stockholm, Sweden.

3Department of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg, Germany.

4Evergrande Center for Immunologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.

5Allergy, Immunology & Rheumatology Division, Center for Musculoskeletal Research, University of Rochester Medical School, Rochester, NY, United States.

6Division of Gastroenterology, Department of Medicine, University of Miami Leonard Miller School of Medicine, Miami, FL, United States.

7Janssen Scientific Affairs, LLC, Horsham, PA, United States.

8Janssen Research & Development, LLC, San Diego, CA, United States.

9Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, United States.

10Janssen Research & Development, LLC, Spring House, PA, United States.

11Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.

12College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.

Abstract

Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease. We review IL-23 biology, IL-23 signaling in IMIDs, and the effect of IL-23 inhibition in treating these diseases. We propose studies to advance IL-23 biology and unravel differences in response to anti-IL-23 therapy. Experimental evidence generated from these investigations could establish a novel molecular ontology centered around IL-23-driven diseases, improve upon current approaches to treating IMIDs with IL-23 inhibition, and ultimately facilitate optimal identification of patients and, thereby, outcomes.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.